Skip to main content

Articles

Page 4 of 37

  1. Recently, several randomized trials have noted improved outcomes with staged percutaneous coronary intervention (PCI) of nonculprit vessels in patients with ST-segment elevation myocardial infarction (STEMI) a...

    Authors: Kongyong Cui, Shuzheng Lyu, Hong Liu, Xiantao Song, Fei Yuan, Feng Xu, Min Zhang, Wei Wang, Mingduo Zhang, Dongfeng Zhang and Jinfan Tian

    Citation: Cardiovascular Diabetology 2019 18:119

    Content type: Original investigation

    Published on:

  2. Cardiac allograft vasculopathy (CAV) is a major cause of morbidity and mortality following heart transplantation (HT). Reduced cardiovascular mortality and morbidity have been reported in non-HT patients treat...

    Authors: Eilon Ram, Jacob Lavee, Alexander Tenenbaum, Robert Klempfner, Enrique Z. Fisman, Elad Maor, Tal Ovdat, Sergei Amunts, Leonid Sternik and Yael Peled

    Citation: Cardiovascular Diabetology 2019 18:118

    Content type: Original investigation

    Published on:

  3. Complication screening is recommended for patients with type 2 diabetes (T2D), but the optimal screening intensity and schedules are unknown. In this study, we evaluated whether intensive versus standard compl...

    Authors: Mario Luca Morieri, Enrico Longato, Marta Mazzucato, Barbara Di Camillo, Arianna Cocchiglia, Lorenzo Gubian, Giovanni Sparacino, Angelo Avogaro, Gian Paolo Fadini and Saula Vigili de Kreutzenberg

    Citation: Cardiovascular Diabetology 2019 18:117

    Content type: Original investigation

    Published on:

  4. To examine the effects of the DPP-4i sitagliptin on CV outcomes during and after incident MI in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).

    Authors: Michael A. Nauck, Darren K. McGuire, Karen S. Pieper, Yuliya Lokhnygina, Timo E. Strandberg, Axel Riefflin, Tuncay Delibasi, Eric D. Peterson, Harvey D. White, Russell Scott and Rury R. Holman

    Citation: Cardiovascular Diabetology 2019 18:116

    Content type: Original investigation

    Published on:

  5. EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant cardioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular di...

    Authors: Guntram Schernthaner, Avraham Karasik, Agnė Abraitienė, Alexander S. Ametov, Zsolt Gaàl, Janusz Gumprecht, Andrej Janež, Susanne Kaser, Katarina Lalić, Boris N. Mankovsky, Evgeny Moshkovich, Marju Past, Martin Prázný, Gabriela Radulian, Lea Smirčić Duvnjak, Ivan Tkáč…

    Citation: Cardiovascular Diabetology 2019 18:115

    Content type: Commentary

    Published on:

  6. Cardiac fat is a cardiovascular biomarker but its importance in patients with type 2 diabetes is not clear. The aim was to evaluate the predictive potential of epicardial (EAT), pericardial (PAT) and total car...

    Authors: Regitse H. Christensen, Bernt Johan von Scholten, Christian S. Hansen, Magnus T. Jensen, Tina Vilsbøll, Peter Rossing and Peter G. Jørgensen

    Citation: Cardiovascular Diabetology 2019 18:114

    Content type: Original investigation

    Published on:

  7. In the light of growing global epidemic of type 2 diabetes mellitus (T2DM), significant efforts are made to discover next-generation biomarkers for early detection of the disease. Multiple mechanisms including...

    Authors: Justyna Pordzik, Daniel Jakubik, Joanna Jarosz-Popek, Zofia Wicik, Ceren Eyileten, Salvatore De Rosa, Ciro Indolfi, Jolanta M. Siller-Matula, Pamela Czajka and Marek Postula

    Citation: Cardiovascular Diabetology 2019 18:113

    Content type: Review

    Published on:

  8. Recent trials suggested that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors reduced cardiovascular events. Comparative effectiveness of these new ...

    Authors: Yue Fei, Man-Fung Tsoi and Bernard Man Yung Cheung

    Citation: Cardiovascular Diabetology 2019 18:112

    Content type: Original investigation

    Published on:

  9. There is no clearly defined temporal relationship between arterial stiffness and diabetes. We aimed to investigate the prospective association between baseline brachial–ankle pulse wave velocity (baPWV) and th...

    Authors: Yuanyuan Zhang, Panpan He, Youbao Li, Yan Zhang, Jianping Li, Min Liang, Guobao Wang, Genfu Tang, Yun Song, Binyan Wang, Chengzhang Liu, Lishun Liu, Yimin Cui, Xiaobin Wang, Yong Huo, Xiping Xu…

    Citation: Cardiovascular Diabetology 2019 18:111

    Content type: Original investigation

    Published on:

  10. The Y-AIDA study was designed to investigate the renal- and home blood pressure (BP)-modulating effects of add-on dapagliflozin treatment in Japanese individuals with type 2 diabetes mellitus (T2DM) and albumi...

    Authors: Sho Kinguchi, Hiromichi Wakui, Yuzuru Ito, Yoshinobu Kondo, Kengo Azushima, Uru Osada, Tadashi Yamakawa, Tamio Iwamoto, Jun Yutoh, Toshihiro Misumi, Kazutaka Aoki, Gen Yasuda, Taishi Yoshii, Takayuki Yamada, Syuji Ono, Tomoko Shibasaki-Kurita…

    Citation: Cardiovascular Diabetology 2019 18:110

    Content type: Original investigation

    Published on:

  11. Inflammation and insulin resistance play crucial roles in the development of type 2 diabetes mellitus (T2DM). We aim to examine the temporal relationship between high-sensitivity C-reactive protein (hsCRP) and...

    Authors: Yinkun Yan, Shengxu Li, Yang Liu, Lydia Bazzano, Jiang He, Jie Mi and Wei Chen

    Citation: Cardiovascular Diabetology 2019 18:109

    Content type: Original investigation

    Published on:

  12. The territory of the right coronary artery (RCA) is smaller than that of the left anterior descending artery. Previous studies have reported conflicting results when considering whether stable RCA-chronic tota...

    Authors: Yunfeng Yan, Mingduo Zhang, Fei Yuan, Hong Liu, Di Wu, Yudong Fan, Xinjing Guo, Feng Xu, Min Zhang, Quanming Zhao and Shuzheng Lyu

    Citation: Cardiovascular Diabetology 2019 18:108

    Content type: Original investigation

    Published on:

  13. Heart failure with preserved ejection fraction (HFpEF) is a difficult disease with high morbidity and mortality rates and lacks an effective treatment. Here, we report the therapeutic effect of dapagliflozin, ...

    Authors: Nannan Zhang, Bin Feng, Xuexing Ma, Kangyun Sun, Guidong Xu and Yafeng Zhou

    Citation: Cardiovascular Diabetology 2019 18:107

    Content type: Original investigation

    Published on:

  14. Cardiovascular outcome trials have documented a strong benefit of sodium glucose cotransporter-2 inhibitors (SGLT2i) on the risk of hospitalization for heart failure (HF) in patients with type 2 diabetes (T2D)...

    Authors: Benedetta Maria Bonora, Saula Vigili de Kreutzenberg, Angelo Avogaro and Gian Paolo Fadini

    Citation: Cardiovascular Diabetology 2019 18:106

    Content type: Original investigation

    Published on:

  15. Although adiponectin is a major adipocytokine that affects the pathogenesis of various cardiovascular diseases, its clinical significance in stroke remains controversial. The purpose of this study was to asses...

    Authors: Zengliang Wang, Bo Li, Yongxin Wang, Aisha Maimaitili, Hu Qin, Geng Dangmurenjiafu and Shuo Wang

    Citation: Cardiovascular Diabetology 2019 18:105

    Content type: Original investigation

    Published on:

  16. To examine the effect of high-intensity interval training (HIIT) on metabolic syndrome (MetS) and body composition in cardiac rehabilitation (CR) patients with myocardial infarction (MI).

    Authors: Yaoshan Dun, Randal J. Thomas, Joshua R. Smith, Jose R. Medina-Inojosa, Ray W. Squires, Amanda R. Bonikowske, Hsuhang Huang, Suixin Liu and Thomas P. Olson

    Citation: Cardiovascular Diabetology 2019 18:104

    Content type: Original investigation

    Published on:

  17. We investigated the association regarding severe hypoglycemia episodes with cardiovascular disease risk and all-cause mortality in patients with type 2 diabetes.

    Authors: Jae-Seung Yun, Yong-Moon Park, Kyungdo Han, Seon-Ah Cha, Yu-Bae Ahn and Seung-Hyun Ko

    Citation: Cardiovascular Diabetology 2019 18:103

    Content type: Original investigation

    Published on:

  18. Myocardial infarction is the main mortality cause in patients with type 2 diabetes (T2DM). Endothelial dysfunction due to reduced bioavailability of nitric oxide (NO) is an early step of atherogenesis. Asymmet...

    Authors: Gaia Chiara Mannino, Serena Pezzilli, Carolina Averta, Anastasia Fuoco, Rosangela Spiga, Elettra Mancuso, Concetta Di Fatta, Francesco Perticone, Sabrina Prudente, Vincenzo Trischitta, Francesco Andreozzi and Giorgio Sesti

    Citation: Cardiovascular Diabetology 2019 18:102

    Content type: Original investigation

    Published on:

  19. Following publication of the original article [1], the authors reported an error in Fig. 3. The bars in the upper right panel that represent heart rate in placebo treated patients is not correct.

    Authors: Maurice B. Bizino, Ingrid M. Jazet, Jos J. M. Westenberg, Huub J. van Eyk, Elisabeth H. M. Paiman, Jan W. A. Smit and Hildebrandus J. Lamb

    Citation: Cardiovascular Diabetology 2019 18:101

    Content type: Correction

    Published on:

    The original article was published in Cardiovascular Diabetology 2019 18:55

  20. Adverse cardiac remodeling after ST-segment elevation myocardial infarction (STEMI) is a major cause for poor cardiovascular outcomes such as heart failure. The predisposing factors and underlying mechanisms r...

    Authors: Chen Die Yang, Ying Shen, Lin Lu, Feng Hua Ding, Zhen Kun Yang, Rui Yan Zhang, Wei Feng Shen, Wei Jin and Xiao Qun Wang

    Citation: Cardiovascular Diabetology 2019 18:100

    Content type: Original investigation

    Published on:

  21. To summarize the four recent sodium-glucose cotransporter 2 inhibitor (SGLT2i) trials: Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI 58), CANagliflozin CardioVascular Assessment Study (CANVAS) Pr...

    Authors: Aaron Y. Kluger, Kristen M. Tecson, Andy Y. Lee, Edgar V. Lerma, Janani Rangaswami, Norman E. Lepor, Michael E. Cobble and Peter A. McCullough

    Citation: Cardiovascular Diabetology 2019 18:99

    Content type: Review

    Published on:

  22. Large changes in health behaviors achieved through intensive lifestyle intervention programs improve cardiovascular disease (CVD) risk factors among adults with type 2 diabetes. However, such interventions are...

    Authors: Jean Strelitz, Amy L. Ahern, Gráinne H. Long, Clare E. Boothby, Nicholas J. Wareham and Simon J. Griffin

    Citation: Cardiovascular Diabetology 2019 18:98

    Content type: Original investigation

    Published on:

  23. Associations between sex hormones and vascular remodeling have been extensively studied, but the results vary widely among different races and sex. We aimed to investigate whether total testosterone (TT), estr...

    Authors: Chiyu Wang, Wen Zhang, Yuying Wang, Heng Wan, Yi Chen, Fangzhen Xia, Kun Zhang, Ningjian Wang and Yingli Lu

    Citation: Cardiovascular Diabetology 2019 18:97

    Content type: Original investigation

    Published on:

  24. Metformin is the most widely prescribed drug to lower glucose and has a definitive effect on the cardiovascular system. The goal of this systematic review and meta-analysis is to assess the effects of metformi...

    Authors: Yechen Han, Hongzhi Xie, Yongtai Liu, Peng Gao, Xufei Yang and Zhujun Shen

    Citation: Cardiovascular Diabetology 2019 18:96

    Content type: Original investigation

    Published on:

  25. It has been reported that the triglyceride-glucose (TyG) index may serve as a simple and credible surrogate marker of insulin resistance (IR). However, its association with macrovascular and microvascular dama...

    Authors: Song Zhao, Shikai Yu, Chen Chi, Ximin Fan, Jiamin Tang, Hongwei Ji, Jiadela Teliewubai, Yi Zhang and Yawei Xu

    Citation: Cardiovascular Diabetology 2019 18:95

    Content type: Original investigation

    Published on:

  26. The definition of class effect for SGLT-2 inhibitors may be based on three concepts: a similar chemical structure, a similar mechanism of action and similar pharmacological effects. We have also assumed that a...

    Authors: Dario Giugliano and Katherine Esposito

    Citation: Cardiovascular Diabetology 2019 18:94

    Content type: Commentary

    Published on:

  27. Individuals with diabetes have remarkably high rates of cardiovascular morbidity and mortality. However, the incremental cardiovascular risk in diabetes is heterogeneous and has often been related to renal inv...

    Authors: Ana Palanca, Esmeralda Castelblanco, Àngels Betriu, Hèctor Perpiñán, Berta Soldevila, José Manuel Valdivielso, Marcelino Bermúdez-Lopez, Carlos Puig-Jové, Manel Puig-Domingo, Per-Henrik Groop, Elvira Fernández, Núria Alonso and Didac Mauricio

    Citation: Cardiovascular Diabetology 2019 18:93

    Content type: Original investigation

    Published on:

  28. Degenerative aortic stenosis (AS), a disease of the elderly, frequently coexists with concomitant diseases, including type 2 diabetes (T2DM) which amplifies the cardiovascular (CV) risk. T2DM affects left vent...

    Authors: Ewa Czestkowska, Agnieszka Rożanowska, Dorota Długosz, Klaudiusz Bolt, Jolanta Świerszcz, Olga Kruszelnicka, Bernadeta Chyrchel and Andrzej Surdacki

    Citation: Cardiovascular Diabetology 2019 18:92

    Content type: Original investigation

    Published on:

  29. Glucagon-like peptide-1 (GLP-1) treatment has been shown to reduce stroke incidence in diabetes and also to be neuroprotective in experimental stroke models. The prognostic value of endogenous levels of GLP-1 ...

    Authors: Martin Larsson, Cesare Patrone, Mia von Euler, Jens J. Holst and David Nathanson

    Citation: Cardiovascular Diabetology 2019 18:91

    Content type: Original investigation

    Published on:

  30. Experimental and clinical data indicate a major influence of diabetes on atherogenesis. We aimed to assess whether the effect of diabetes on long-term mortality in asymptomatic patient with carotid stenosis is...

    Authors: Matthias Hoke, Martin Schillinger, Erich Minar, Georg Goliasch, Christoph J. Binder and Florian J. Mayer

    Citation: Cardiovascular Diabetology 2019 18:90

    Content type: Original investigation

    Published on:

  31. The triglyceride-glucose index (TyG index) is a tool for insulin resistance evaluation, however, little is known about its association with coronary artery disease (CAD), which is the major cardiovascular deat...

    Authors: Alessandra da Silva, Ana Paula Silva Caldas, Helen Hermana Miranda Hermsdorff, Ângela Cristine Bersch-Ferreira, Camila Ragne Torreglosa, Bernardete Weber and Josefina Bressan

    Citation: Cardiovascular Diabetology 2019 18:89

    Content type: Original investigation

    Published on:

  32. Hypertension is one of the strongest risk factors for stroke in the general population, while systolic blood pressure has been shown to independently increase the risk of stroke in type 1 diabetes. The aim of ...

    Authors: Stefanie Hägg-Holmberg, Emma H. Dahlström, Carol M. Forsblom, Valma Harjutsalo, Ron Liebkind, Jukka Putaala, Turgut Tatlisumak, Per-Henrik Groop and Lena M. Thorn

    Citation: Cardiovascular Diabetology 2019 18:88

    Content type: Original investigation

    Published on:

  33. South Asians have a high risk to develop type 2 diabetes, which may be related to substantial ectopic fat deposition. Since glucagon-like peptide-1 analogues can reduce ectopic fat accumulation, the aim of the...

    Authors: Huub J. van Eyk, Elisabeth H. M. Paiman, Maurice B. Bizino, Paul de Heer, Petronella H. Geelhoed-Duijvestijn, Aan V. Kharagjitsingh, Johannes W. A. Smit, Hildo J. Lamb, Patrick C. N. Rensen and Ingrid M. Jazet

    Citation: Cardiovascular Diabetology 2019 18:87

    Content type: Original investigation

    Published on:

  34. Branched chain amino acids (BCAA) can impair insulin signaling, and cardiac insulin resistance can occur in the failing heart. We, therefore, determined if cardiac BCAA accumulation occurs in patients with dil...

    Authors: Golam M. Uddin, Liyan Zhang, Saumya Shah, Arata Fukushima, Cory S. Wagg, Keshav Gopal, Rami Al Batran, Simran Pherwani, Kim L. Ho, Jamie Boisvenue, Qutuba G. Karwi, Tariq Altamimi, David S. Wishart, Jason R. B. Dyck, John R. Ussher, Gavin Y. Oudit…

    Citation: Cardiovascular Diabetology 2019 18:86

    Content type: Original investigation

    Published on:

  35. Recent large-scale clinical trials have shown that SGLT2-inhibitors reduce cardiovascular events in diabetic patients. However, the regulation and functional role of cardiac sodium–glucose cotransporter (SGLT1...

    Authors: Akira Yoshii, Tomohisa Nagoshi, Yusuke Kashiwagi, Haruka Kimura, Yoshiro Tanaka, Yuhei Oi, Keiichi Ito, Takuya Yoshino, Toshikazu D. Tanaka and Michihiro Yoshimura

    Citation: Cardiovascular Diabetology 2019 18:85

    Content type: Original investigation

    Published on:

  36. Heart disease continues to affect health outcomes globally, accounting for a quarter of all deaths in the United States. Despite the improvement in the development and implementation of guideline-directed medi...

    Authors: Omar Sheikh, Anthony G. Vande Hei, Ayman Battisha, Tarek Hammad, Son Pham and Robert Chilton

    Citation: Cardiovascular Diabetology 2019 18:84

    Content type: Review

    Published on:

  37. Perivascular adipose tissue (PVAT) plays a critical role in the pathogenesis of cardiovascular disease. It is unclear whether inhibition of sodium glucose cotransporter 2 (SGLT2) in subjects with type 2 diabet...

    Authors: Kentaro Mori, Kyoichiro Tsuchiya, Suguru Nakamura, Yasutaka Miyachi, Kumiko Shiba, Yoshihiro Ogawa and Kenichiro Kitamura

    Citation: Cardiovascular Diabetology 2019 18:83

    Content type: Original investigation

    Published on:

  38. We investigated whether or to what extent the interaction of lipoprotein (a) [Lp(a)] with cholesterol-containing lipids was associated with angiographic coronary collateralization in type 2 diabetic patients w...

    Authors: Ying Shen, Shuai Chen, Yang Dai, Xiao Qun Wang, Rui Yan Zhang, Zhen Kun Yang, Jian Hu, Lin Lu, Feng Hua Ding and Wei Feng Shen

    Citation: Cardiovascular Diabetology 2019 18:82

    Content type: Original investigation

    Published on:

  39. In patients with diabetes, death and cardiovascular diseases are attributed to classical risk factors such as hypertension, dyslipidemia, and smoking habit, whereas these events are attributed to frailty in th...

    Authors: Satoshi Ida, Ryutaro Kaneko, Kanako Imataka and Kazuya Murata

    Citation: Cardiovascular Diabetology 2019 18:81

    Content type: Original investigation

    Published on:

  40. Saroglitazar, a novel dual peroxisome proliferator activated receptor (PPAR) agonist, in clinical trials, has shown an improvement in lipid and glycemic parameters through the PPAR-α and γ agonist actions, res...

    Authors: Upendra Kaul, Deven Parmar, K. Manjunath, Mitesh Shah, Krupi Parmar, Kishor P. Patil and Ashok Jaiswal

    Citation: Cardiovascular Diabetology 2019 18:80

    Content type: Review

    Published on:

  41. Prevalent diabetes at the time of heart failure (HF) diagnosis is associated with a higher risk of death, but the incidence and prognostic importance of new-onset diabetes in patients with established HF remai...

    Authors: B. Zareini, Rasmus Rørth, Anders Holt, Ulrik M. Mogensen, Christian Selmer, Gunnar Gislason, Morten Schou, Lars Køber, Christian Torp-Pedersen, Morten Lamberts and Søren Lund Kristensen

    Citation: Cardiovascular Diabetology 2019 18:79

    Content type: Original investigation

    Published on:

  42. Diabetes mellitus is a chronic disease that impacts an increasing percentage of people each year. Among its comorbidities, diabetics are two to four times more likely to develop cardiovascular diseases. While ...

    Authors: Quincy A. Hathaway, Skyler M. Roth, Mark V. Pinti, Daniel C. Sprando, Amina Kunovac, Andrya J. Durr, Chris C. Cook, Garrett K. Fink, Tristen B. Cheuvront, Jasmine H. Grossman, Ghadah A. Aljahli, Andrew D. Taylor, Andrew P. Giromini, Jessica L. Allen and John M. Hollander

    Citation: Cardiovascular Diabetology 2019 18:78

    Content type: Original investigation

    Published on:

  43. Microvascular blood flow (MBF) impairment in patients with lower extremity arterial disease (LEAD) is associated with more severe major adverse limb events (MALE). The contribution of ticagrelor, a P2Y12 antag...

    Authors: Robert S. Rosenson, Qinzhong Chen, Sherwin D. Najera, Prakash Krishnan, Martin L. Lee and Daniel J. Cho

    Citation: Cardiovascular Diabetology 2019 18:77

    Content type: Original investigation

    Published on:

  44. The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0 mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in subjects with type 2 diabetes (T2D) and high C...

    Authors: Lawrence A. Leiter, Stephen C. Bain, Irene Hramiak, Esteban Jódar, Sten Madsbad, Theis Gondolf, Thomas Hansen, Ingrid Holst and Ildiko Lingvay

    Citation: Cardiovascular Diabetology 2019 18:73

    Content type: Original investigation

    Published on:

  45. Reports that sodium glucose cotransporter 2 inhibitors decrease cardiovascular death and events in patients with diabetes have attracted attention in the cardiology field. We conducted a study of canagliflozin...

    Authors: Akira Sezai, Hisakuni Sekino, Satoshi Unosawa, Makoto Taoka, Shunji Osaka and Masashi Tanaka

    Citation: Cardiovascular Diabetology 2019 18:76

    Content type: Original investigation

    Published on:

  46. To examine whether glycemic control of gestational diabetes mellitus (GDM) could modify the risk for future maternal metabolic and cardiovascular morbidities.

    Authors: Enav Yefet, Naama Schwartz, Basma Sliman, Avraham Ishay and Zohar Nachum

    Citation: Cardiovascular Diabetology 2019 18:75

    Content type: Original investigation

    Published on:

  47. Type-2 diabetes mellitus is one of the major risk factors of atherosclerosis, particularly in peripheral artery disease (PAD). Several studies have documented a correlation between omentin-1 serum levels, athe...

    Authors: Federico Biscetti, Elisabetta Nardella, Nicola Bonadia, Flavia Angelini, Dario Pitocco, Angelo Santoliquido, Marco Filipponi, Raffaele Landolfi and Andrea Flex

    Citation: Cardiovascular Diabetology 2019 18:74

    Content type: Original investigation

    Published on:

  48. The global burden of type 2 diabetes mellitus (T2DM), together with the presence of cardiovascular risk in this population, is reaching pandemic levels. A prominent feature of T2DM is chronic and systemic infl...

    Authors: Shehan N. Randeria, Greig J. A. Thomson, Theo A. Nell, Timothy Roberts and Etheresia Pretorius

    Citation: Cardiovascular Diabetology 2019 18:72

    Content type: Original investigation

    Published on:

  49. In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events...

    Authors: Jean-Charles Fruchart, Raul D. Santos, Carlos Aguilar-Salinas, Masanori Aikawa, Khalid Al Rasadi, Pierre Amarenco, Philip J. Barter, Richard Ceska, Alberto Corsini, Jean-Pierre Després, Patrick Duriez, Robert H. Eckel, Marat V. Ezhov, Michel Farnier, Henry N. Ginsberg, Michel P. Hermans…

    Citation: Cardiovascular Diabetology 2019 18:71

    Content type: Review

    Published on:

  50. The clinical benefit of aspirin for the primary prevention of cardiovascular disease (CVD) in diabetes remains uncertain. To evaluate the efficacy and safety of aspirin for the primary prevention of cardiovasc...

    Authors: Samuel Seidu, Setor K. Kunutsor, Howard D. Sesso, J. M. Gaziano, J. E. Buring, Maria Carla Roncaglioni and Kamlesh Khunti

    Citation: Cardiovascular Diabetology 2019 18:70

    Content type: Review

    Published on:

journal logo
Submit manuscript

Annual Journal Metrics

Cardiovascular Diabetology

ISSN: 1475-2840